|Systematic (IUPAC) name|
|CAS Registry Number|
|Molecular mass||366.335 g/mol|
HT-2157 (former code name SNAP-37889) is a drug which acts as a selective non-peptide antagonist for the receptor GAL-3, which is usually activated by the neuropeptide galanin. Blocking this receptor with HT-2157 produced increased serotonin release, as well as producing antidepressant and anxiolytic effects in animal studies, and it was also being researched for treatment of cognitive dysfunction. All human clinical trials were terminated due to safety concerns however, and new GAL-3 antagonists are now being sought instead.
- Winter Meeting December 2005Proceedings of the British Pharmacological SocietyRowley HL, et al. Effects of HT 2157, a galanin 3 receptor antagonist, on extracellular levels of 5 HT in various brain regions of freely moving rats.
- Swanson CJ, et al. Anxiolytic- and antidepressant-like profiles of the galanin-3 receptor (Gal3) antagonists SNAP 37889 and SNAP 398299. PNAS 2005; 102(48):17489-17494. doi 10.1073/pnas.0508970102
- Kaplan AP. Enteric-coated HT-2157 compositions and methods of their use. Patent US 8277842, filed Jan 20th 2012.